BioPharma Credit

BioPharma Credit EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioPharma Credit (BPCR.L) as of Nov 21, 2026 is 129.85 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 122.18 M USD — a change of 6.28% (higher).

EBITDA

129.85 MUSD

YoY

6.28%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioPharma Credit is 2025 129.85 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioPharma Credit was 2024 122.18 M USD. It decreases by 6.28% higher compared to the previous year.

The BioPharma Credit EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
70.15 M USD
Jan 1, 2019
122.33 M USD
Jan 1, 2020
89.14 M USD
Jan 1, 2021
84.96 M USD
Jan 1, 2022
182.31 M USD
Jan 1, 2023
108.45 M USD
Jan 1, 2024
122.18 M USD
Jan 1, 2025
129.85 M USD
The BioPharma Credit EBITDA history
YEAREBITDAYoY
129.85 MUSD+6.28%
122.18 MUSD+12.66%
108.45 MUSD-40.51%
182.31 MUSD+114.59%
84.96 MUSD-4.69%
89.14 MUSD-27.13%
122.33 MUSD+74.38%
70.15 MUSD+158.63%
27.12 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioPharma Credit Stock analysis

What does BioPharma Credit do? BioPharma Credit PLC was founded in 2017 and is an investment company specializing in financing in the biopharmaceutical and medical field. The company's goal is to identify investment opportunities in the rapidly growing biopharmaceutical market and generate lucrative returns for investors. BioPharma Credit's business model is based on providing loans to biotechnology and pharmaceutical companies. These loans are used to finance important projects and research that contribute to the development of new drugs and treatment methods. In return, the companies receive interest payments and loan repayments according to the agreements in the contract. BioPharma Credit pursues a differentiated strategy and invests in various sectors of the biopharmaceutical industry, such as cancer treatments, immunotherapies, or rare diseases. This includes riskier but potentially very profitable projects such as clinical trials or the market entry of new drugs. BioPharma Credit's portfolio currently includes approximately 26 investments in various areas of the biopharmaceutical industry. The company works closely with experienced partners such as the pharmaceutical company Pharmakia or the analysis firm IHS to conduct comprehensive due diligence and carefully assess opportunities and risks. Another important element of BioPharma Credit's business model is the investors. Most of BioPharma Credit's investors are institutional investors such as pension funds or insurance companies. Therefore, the company also takes into account the needs and requirements of these investors in the selection of borrowers and projects. BioPharma Credit offers its investors high transparency and protection against potential risks. All investments are made through a GmbH structure with fixed terms and fixed interest payments. In addition, the portfolio is regularly monitored and adjusted by an expert team to minimize risks and seize opportunities. Overall, BioPharma Credit offers its investors an attractive opportunity to benefit from the opportunities in the rapidly growing biopharmaceutical market without directly entering the risks and challenges of the biopharmaceutical industry. At the same time, BioPharma Credit contributes to driving important innovations and advancements in medicine and thereby generating societal and health benefits. One of BioPharma Credit's most successful investments in recent years, for example, was a loan to the British biotechnology company Orchard Therapeutics. This company specializes in the development of gene therapies for rare diseases. The loan from BioPharma Credit helped Orchard Therapeutics conduct a clinical trial and enter the market. Orchard Therapeutics' gene therapy has since been approved by the European Medicines Agency and has the potential to improve the lives of millions of people worldwide. Overall, the success story of BioPharma Credit demonstrates how investments in the field of biopharmaceuticals and medicine can contribute to driving important innovations and advancements in medicine while also achieving attractive returns for investors. The company has established itself as an experienced and reliable partner that, thanks to its expertise and networks, will continue to identify and realize successful investments in the biopharmaceutical sector in the future. BioPharma Credit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioPharma Credit stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioPharma Credit is 129.85 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioPharma Credit changed from 122.18 M USD to 129.85 M USD, representing a 6.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BioPharma Credit since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BioPharma Credit historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioPharma Credit

All Key Metrics — BioPharma Credit